CareDx (CDNA) Projected to Post Quarterly Earnings on Wednesday

CareDx (NASDAQ:CDNA) will likely be posting its quarterly earnings results after the market closes on Wednesday, February 26th. Analysts expect CareDx to post earnings of $0.05 per share and revenue of $84.56 million for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

CareDx Stock Down 4.7 %

CDNA opened at $22.29 on Monday. The stock has a market cap of $1.20 billion, a price-to-earnings ratio of -8.26 and a beta of 1.87. CareDx has a twelve month low of $7.42 and a twelve month high of $34.84. The company’s 50-day moving average price is $22.69 and its two-hundred day moving average price is $25.41.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on CDNA shares. BTIG Research decreased their target price on shares of CareDx from $40.00 to $35.00 and set a “buy” rating on the stock in a report on Tuesday, November 5th. StockNews.com cut shares of CareDx from a “buy” rating to a “hold” rating in a research note on Tuesday, February 18th. Wells Fargo & Company raised shares of CareDx from an “underweight” rating to an “equal weight” rating and dropped their price target for the company from $28.00 to $24.00 in a research report on Wednesday, January 15th. Finally, HC Wainwright reiterated a “neutral” rating and issued a $26.00 price target on shares of CareDx in a research note on Tuesday, January 14th. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $28.33.

Insider Buying and Selling

In other CareDx news, Director Peter Maag sold 5,000 shares of the firm’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $25.00, for a total value of $125,000.00. Following the completion of the sale, the director now directly owns 330,024 shares of the company’s stock, valued at $8,250,600. This trade represents a 1.49 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.90% of the stock is owned by corporate insiders.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.